An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.

Pfizer402 enrolled

Overview

A study designed to assess the efficacy, toleration and safety of SS-RBX for the treatment of stress urinary incontinence.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

402

Conditions

Urinary Incontinence, Stress

Interventions

SS-RBXDRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinically significant stress urinary incontinence Exclusion Criteria: * History or evidence of any relevant confounding urological or neurological disease

Locations (95)

Outcomes

Primary Outcomes

Proof of concept study to assess the efficacy, tolerability and safety of SS-RBX vs. placebo in the treatment of SUI.

Secondary Outcomes

To evaluate whether an upward dose adjustment affects the tolerability of SS-RBX.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Anchorage, Alaska, United States

Pfizer Investigational Site

Sun City, Arizona, United States

Pfizer Investigational Site

Tucson, Arizona, United States

Pfizer Investigational Site

Tucson, Arizona, United States

Pfizer Investigational Site

Little Rock, Arkansas, United States

Pfizer Investigational Site

Atherton, California, United States

Pfizer Investigational Site

Carmichael, California, United States

Pfizer Investigational Site

Laguna Woods, California, United States

Pfizer Investigational Site

Murrieta, California, United States

Pfizer Investigational Site

Newport Beach, California, United States

...and 85 more locations